Protai, a Tel Aviv, Israel-based AI-powered drug discovery startup, announced its emergence from stealth, along with an $8 million seed financing round co-led by Grove Ventures and Pitango HealthTech.
The funding will be used to further develop Protai's platform, accelerate its discovery programs and enhance its partnerships with pharmaceutical companies.
Company: Protei Bio Ltd.
Round: Seed Round
Funding Month: January 2022
Lead Investors: Grove Ventures and Pitango HealthTech
Company Website: https://www.protai.bio/
Software Category: AI-powered drug discovery
About the Company: Founded by Eran Seger and Kirill Pevzner, Protai empowers drug discovery with proteomics and artificial intelligence to unlock new layers of biological insights and to combat complex diseases. Protai has built an end-to-end AI-based platform that comprehensively maps the course of a disease on the protein level, enhancing the ability to observe cellular function and thereby improving the way new drugs are discovered. Protai's platform has leaped to solve how drug candidates are created and validated, facilitating quicker and more advanced drug discovery.